Gynecologic Oncology | Specialty

Heterogeneity of Soft Tissue Sarcomas

November 14th 2017

IDO Plus PD-1 Inhibitor Combo Sparks Responses in Bladder and Cervical Cancers

November 12th 2017

The combination of nivolumab and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers.

Dr. Luke on Combining an IDO Inhibitor With Nivolumab in Advanced Cancers

November 12th 2017

Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses a study evaluating the IDO1 inhibitor BMS-986205 as a monotherapy and in combination with nivolumab in patients with advanced cancers.

Bevacizumab Biosimilar Nears European Approval

November 11th 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of the bevacizumab biosimilar ABP 215 for the treatment of patients across several tumor types.

How Reliable Is PD-L1 Expression as a Predictor of Immune Response?

November 9th 2017

There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.

Endometrial Cancer Enters Immunotherapy Age

November 9th 2017

The tumor-site agnostic FDA approval of the PD-1 inhibitor pembrolizumab (Keytruda) for patients with microsatellite instability-high or mismatch repair deficient solid tumors has helped propel endometrial cancer into the immunotherapy age.

Cisplatin Chemoradiation Proves Benefit in Stage IIIB Cervical Cancer

November 9th 2017

Umesh Mahantshetty, MD, shares his insight on the state of cervical cancer treatment in developing countries.

Dr. Ghamande Discusses GOG/NRG 0265 Study in Cervical Cancer

November 9th 2017

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the GOG/NRG-0265 study in cervical cancer.

Dr. Haldorsen on the Role of Imaging in the Diagnosis of Endometrial Cancer

November 8th 2017

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the role of imaging in the diagnosis of endometrial cancer.

Dr. Bosch on the HPV Vaccination in the Prevention of Cervical Cancer

November 8th 2017

Xavier Bosch, MD, MPH, Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia–Catalan Institute of Oncology, introduces a second-generation vaccination against the human papilloma virus (HPV) for the prevention of cervical cancer.

Tisotumab Vedotin Shows Clinical Benefit and Ongoing Responses in Cervical Cancer

November 7th 2017

A first-in-human study showed that the antibody drug conjugate tisotumab vedotin was well-tolerated and provided promising anti-tumor activity in patients with relapsed, recurrent, and/or metastatic cervical cancer.

Dr. Mahantshetty Discusses Results of Chemoradiation in Cervical Cancer

November 7th 2017

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses the results of a trial of chemoradiation in patients with cervical cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

Dr. Zamarin on the Role of Pembrolizumab in Endometrial Cancer

November 7th 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of pembrolizumab (Keytruda) for patients with endometrial cancer.

Pembrolizumab Demonstrates Safety and Efficacy in Cervical Cancer

November 4th 2017

In phase Ib results from the KEYNOTE-028 trial, pembrolizumab (Keytruda) was found to be active in cervical cancer while demonstrating safety results similar to previous studies with the PD-1 inhibitor.

FDA Accepts sBLA for Bevacizumab in First-Line Ovarian Cancer

October 27th 2017

The FDA has accepted a supplemental biologics license application for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer.

Expert Discusses Immunotherapy Across Gynecologic Malignancies

October 24th 2017

Dmitriy Zamarin, MD, PhD, discusses the role of immunotherapy for patients with gynecologic malignancies.

Neoadjuvant Chemo Linked to Above 95% OS in Squamous Cell Cervical Cancer

October 23rd 2017

Investigators sought to assess the efficacy of adjuvant surgery after concurrent chemoradiotherapy in patients with bulky squamous cell carcinoma of the uterine cervix

Hydrocortisone Reduces Hypersensitivity Reactions in Women With Gynecologic Cancers

October 13th 2017

Adding IV hydrocortisone to standard dexamethasone prophylaxis reduced the incidence of hypersensitivity reactions in women undergoing paclitaxel-based treatment for gynecologic cancers

Dr. Zamarin on the Future Treatment Landscape of Gynecologic Malignancies

October 13th 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future treatment landscape for patients with gynecologic malignancies.

Dr. Ginsburg on Determining Genetic Testing in Gynecologic Malignancies

October 13th 2017

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses determining which patients should receive genetic testing for gynecologic malignancies.